Home Biosimilar Antibodies Transmembrane Transporters Sodium Channel inhibitor Lifastuzumab vedotin For research use only.
Not for use in humans.

Lifastuzumab vedotin

Synonyms: LIFA, DNIB0600A, RG-7599

Lifastuzumab vedotin (LIFA, DNIB0600A, RG-7599) is an antibody-drug conjugate (ADC) composed of a humanized anti-NaPi2b monoclonal antibody and an anti-mitotic cytotoxic agent, monomethyl auristatin E (MMAE) . Lifastuzumab vedotin is used in the treatment of platinum-resistant ovarian cancer.

Lifastuzumab vedotin

CAS No. 1401812-88-1

Click to purchase the isotype control of Lifastuzumab vedotin

Purity & Quality Control

Batch: D401001 Purity: 99% Protein concentration: 8.79mg/ml Endotoxin Level: ＜1EU/mg
99

Choose Selective Sodium Channel Inhibitors

Biological Activity

Description Lifastuzumab vedotin (LIFA, DNIB0600A, RG-7599) is an antibody-drug conjugate (ADC) composed of a humanized anti-NaPi2b monoclonal antibody and an anti-mitotic cytotoxic agent, monomethyl auristatin E (MMAE) . Lifastuzumab vedotin is used in the treatment of platinum-resistant ovarian cancer.

Product Details

CAS No. 1401812-88-1
ADC antiody Lifastuzumab
ADC cytotoxin MMAE
Formulation 1xPBS
Storage
(From the date of receipt)		 Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Tech Support

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Lifastuzumab vedotin | Lifastuzumab vedotin supplier | purchase Lifastuzumab vedotin | Lifastuzumab vedotin cost | Lifastuzumab vedotin manufacturer | order Lifastuzumab vedotin | Lifastuzumab vedotin distributor